Hims & Hers Health (NYSE:HIMS) Posts Earnings Results, Misses Expectations By $0.01 EPS

Key Points

• Hims & Hers Health reported quarterly earnings of $0.17 per share, meeting analyst expectations, with a net margin of 9.24% and a return on equity of 22.75%.
• Shares of Hims & Hers Health increased by 1.3% to $63.38, supported by significant trading volume of over 35 million shares.
• Despite the positive earnings report, analysts maintain a mixed outlook, with an average rating of "Hold" and a target price of $39.83 for the stock.

Hims & Hers Health (NYSE:HIMS - Get Free Report) announced its earnings results on Monday. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01), Zacks reports. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. During the same quarter last year, the firm posted $0.06 earnings per share. The business's quarterly revenue was up 72.6% compared to the same quarter last year. Hims & Hers Health updated its Q3 2025 guidance to EPS and its FY 2025 guidance to EPS.

Hims & Hers Health Trading Up 0.9%

Shares of HIMS traded up $0.44 during midday trading on Friday, hitting $51.49. The stock had a trading volume of 13,145,967 shares, compared to its average volume of 34,282,594. The stock's 50 day moving average is $53.76 and its 200 day moving average is $44.79. The firm has a market cap of $11.53 billion, a PE ratio of 64.27, a price-to-earnings-growth ratio of 2.16 and a beta of 2.08. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 1.32. Hims & Hers Health has a 1 year low of $13.47 and a 1 year high of $72.98.

Insider Activity

In other news, insider Michael Chi sold 17,102 shares of Hims & Hers Health stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $59.75, for a total transaction of $1,021,844.50. Following the completion of the sale, the insider directly owned 278,654 shares in the company, valued at approximately $16,649,576.50. This trade represents a 5.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Andrew Dudum sold 128,127 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $56.76, for a total transaction of $7,272,488.52. Following the completion of the transaction, the chief executive officer directly owned 160,215 shares in the company, valued at $9,093,803.40. This represents a 44.44% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 737,704 shares of company stock valued at $40,644,035. 13.71% of the stock is currently owned by insiders.

Institutional Trading of Hims & Hers Health

A hedge fund recently bought a new stake in Hims & Hers Health stock. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,018 shares of the company's stock, valued at approximately $30,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Analyst Ratings Changes

HIMS has been the topic of several analyst reports. Needham & Company LLC reiterated a "hold" rating on shares of Hims & Hers Health in a research report on Tuesday. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Piper Sandler reiterated a "neutral" rating and issued a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Truist Financial lifted their target price on shares of Hims & Hers Health from $45.00 to $48.00 and gave the company a "hold" rating in a research note on Thursday, July 17th. Finally, TD Cowen cut Hims & Hers Health from a "buy" rating to a "hold" rating and decreased their price target for the company from $44.00 to $30.00 in a report on Tuesday, April 29th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of "Hold" and an average price target of $39.83.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.